

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) An electrotransport device, comprising:
first and second electrodes;
a first reservoir adapted to receive an active agent formulation;
a second reservoir adapted to receive an electrolyte formulation,
said first reservoir being in communication with said electrode,
said second reservoir being in communication with said second electrode;
a power source;
electronic circuitry in communication with at least said first and second electrodes;
a non-conductive reservoir housing having an internal cavity adapted to receive
containing said first electrode and said first reservoir, said reservoir housing including an
integral electrically conductive element integrally molded within the non-conductive housing
and having a first end in communication with said first reservoir and a second end that is
disposed on the outside of said reservoir housing and extends therefrom, said second end of
said conductive element being adapted to be operatively connected to said power source,
whereby electrical communication between said first reservoir, said electronic circuitry and
said power source is provided.
2. (original) The electrotransport device of Claim 1, wherein said power source is in
communication with said electronic circuitry and said second end of said conductive element
is adapted to be connected to said electronic circuitry.
3. (original) The electrotransport device of Claim 1, wherein said conductive element
comprises a substantially planar member.
4. (original) The electrotransport device of Claim 2, wherein said conductive element is
substantially flexible.

5. (original) The electrotransport device of Claim 1, wherein said conductive element includes a base member having a conductive coating disposed thereon.
6. (currently amended) The electrotransport device of Claim 1, wherein said active agent formulation includes a therapeutic agent selected from the group consisting of anti-infectives, ~~including antibiotics and antiviral agents~~; analgesics, ~~including fentanyl, sufentanil, remifentanil, buprenorphine and analgesic combinations~~; anesthetics; anorexics; antiarthritics; antiasthmatic agents; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihistamines; anti-inflammatory agents; antimigraine preparations; antimotion sickness preparations ~~such as scopolamine and ondansetron~~; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics, ~~including gastrointestinal and urinary~~; anticholinergics; sympathomimetics; xanthine derivatives; cardiovascular preparations, ~~including calcium channel blockers~~; beta blockers; beta-agonists, ~~including dobutamine and ritodrine~~; antiarrhythmics; antihypertensives, ~~including atenolol~~; ACE inhibitors ~~such as ranitidine~~; diuretics; vasodilators, ~~including general, coronary, peripheral, and cerebral~~; central nervous system stimulants; cough and cold preparations; decongestants; diagnostics; hormones, ~~including parathyroid hormone~~; hypnotics; immunosuppressants; muscle relaxants; parasympatholytics; parasympathomimetics; prostaglandins; proteins; peptides; psychostimulants; sedatives; and tranquilizers.
7. (new) The electrotransport device of Claim 6, wherein the anti-infective is an antibiotic or antiviral agent.
8. (new) The electrotransport device of Claim 6, wherein the analgesic is fentanyl, sufentanil, remifentanil, buprenorphine or an analgesic combination.
9. (new) The electrotransport device of Claim 6, wherein the antimotion sickness preparation is scopolamine or ondansetron.

10. (new) The electrotransport device of Claim 6, wherein the antispasmodic is a gastrointestinal or urinary antispasmodic.
11. (new) The electrotransport device of Claim 6, wherein the cardiovascular preparation is a calcium channel blocker.
12. (new) The electrotransport device of Claim 6, wherein the beta-agonist is dobutamine or ritodrine.
13. (new) The electrotransport device of Claim 6, wherein the antihypertensive is atenolol.
14. (new) The electrotransport device of Claim 6, wherein the ACE inhibitor is ranitidine.
15. (new) The electrotransport device of Claim 6, wherein the vasodilator is a general, coronary, peripheral, or cerebral vasodilator.
16. (new) The electrotransport device of Claim 6, wherein the hormone is parathyroid hormone.